amantadine and MS (Multiple Sclerosis) studies

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source

Research Excerpts

Excerpt	Relevance	Reference
"Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting."	9.41	Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021)
"The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS."	9.27	Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018)
"One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS."	9.17	Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013)
"The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)."	9.16	Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012)
"We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures."	9.09	Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000)
"Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS."	9.08	The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996)
"Amantadine-treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0."	9.08	Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995)
"In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six."	9.06	Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988)
"We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo."	9.05	Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985)
"The efficacy of amantadine in reducing fatigue in people with MS is poorly documented, as well as its tolerability."	8.84	Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007)
"Amantadine treatment is overall well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented and there is insufficient evidence to make recommendations to guide prescribing."	8.82	Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003)
"Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis."	8.31	Amantadine toxicity causing visual hallucinations. ( Barbara, JM; Pace, A, 2023)
"To report a patient with secondary progressive multiple sclerosis (SPMS) who developed late-onset side effects of amantadine which were initially felt to represent a progression of her SPMS."	8.02	Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021)
"Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research."	7.79	Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013)
"The authors report the successful use of Descemet's stripping automated endothelial keratoplasty (DSAEK) to treat a 45-year-old woman with amantadine-associated corneal edema."	7.76	Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. ( Dupps, WJ; Hood, CT; Langston, RH; Schoenfield, LR, 2010)
"Amantadine can cause corneal edema that begins a few months to several years after institution of therapy, and the edema can occur even in a corneal graft."	7.74	Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. ( Galor, A; Hollyfield, JG; Jeng, BH; Langston, RH; Lee, MS; McMahon, JT; Meisler, DM; Schoenfield, L, 2008)
" Numeric dose response was seen for some secondary efficacy outcomes and adverse events."	7.11	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. ( Cameron, MH; Cohen, JA; Elfont, R; Goldman, MD; Goodman, AD; Johnson, R; Llorens, L; Miller, AE; Patni, R; Rollins, A, 2022)
"Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed."	7.01	Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021)
" The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia."	6.90	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. ( Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019)
"Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment."	6.66	Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989)
"Acupuncture combined with amantadine and routine care compared with amantadine and routine care alone appears to be an effective short-term treatment for reducing fatigue and enhancing quality of life, including physical function and mental status, in patients with RRMS."	5.69	Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial. ( Kazemi, AH; Khodaie, F; Naser Moghadasi, A; Zhao, B, 2023)
"Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection."	5.56	Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020)
"Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting."	5.41	Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021)
"We present a case of amantadine-induced coma in a patient with multiple sclerosis and end-stage renal disease."	5.29	Amantadine-induced coma. ( Ito, V; Macchio, GJ; Sahgal, V, 1993)
"The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS."	5.27	Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018)
"One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS."	5.17	Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013)
"The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)."	5.16	Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012)
"We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures."	5.09	Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000)
"Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS."	5.08	The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996)
"Amantadine-treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0."	5.08	Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995)
"In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six."	5.06	Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988)
"We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo."	5.05	Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985)
" Search terms included multiple sclerosis, fatigue, medication treatments, amantadine, modafinil, aspirin, acetyl-l-carnitine, pemoline, 4-aminopyridine and randomized controlled trial (RCT)."	4.95	Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. ( Deng, XY; Wang, L; Yang, TT; Yu, G, 2017)
" We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis."	4.91	Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015)
" In the completed study, adult patients with relapsing-remitting and secondary progressive MS were exposed to both acetyl L-carnitine 2 grams daily and amantadine 200 mg daily The effects of carnitine on fatigue are unclear."	4.88	Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2012)
" Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis."	4.86	Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010)
"The efficacy of amantadine in reducing fatigue in people with MS is poorly documented, as well as its tolerability."	4.84	Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007)
"Amantadine treatment is overall well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented and there is insufficient evidence to make recommendations to guide prescribing."	4.82	Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003)
" Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term."	4.80	Treatments for fatigue in multiple sclerosis: a rapid and systematic review. ( Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R, 2000)
"Amantadine hydrochloride is a well-known antiviral agent that has been used for the prevention of influenza A2, the treatment of Parkinson disease, and, more recently, multiple sclerosis."	4.78	Fetal outcome following intrauterine amantadine exposure. ( Koren, G; Levy, M; Pastuszak, A, 1991)
"Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis."	4.31	Amantadine toxicity causing visual hallucinations. ( Barbara, JM; Pace, A, 2023)
"To report a patient with secondary progressive multiple sclerosis (SPMS) who developed late-onset side effects of amantadine which were initially felt to represent a progression of her SPMS."	4.02	Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021)
"Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research."	3.79	Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013)
"The authors report the successful use of Descemet's stripping automated endothelial keratoplasty (DSAEK) to treat a 45-year-old woman with amantadine-associated corneal edema."	3.76	Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. ( Dupps, WJ; Hood, CT; Langston, RH; Schoenfield, LR, 2010)
"Amantadine can cause corneal edema that begins a few months to several years after institution of therapy, and the edema can occur even in a corneal graft."	3.74	Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. ( Galor, A; Hollyfield, JG; Jeng, BH; Langston, RH; Lee, MS; McMahon, JT; Meisler, DM; Schoenfield, L, 2008)
"In the last several years, amantadine has been increasingly prescribed for akinesia in Parkinson's disease and to combat fatigue associated with multiple sclerosis."	3.73	Amantadine-induced livedo reticularis: a report of two cases. ( Cook-Norris, RH; Hayes, BB; Miller, JL; Rodriguez, A; Zic, JA, 2006)
" Numeric dose response was seen for some secondary efficacy outcomes and adverse events."	3.11	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. ( Cameron, MH; Cohen, JA; Elfont, R; Goldman, MD; Goodman, AD; Johnson, R; Llorens, L; Miller, AE; Patni, R; Rollins, A, 2022)
"Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed."	3.01	Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021)
" The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia."	2.90	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. ( Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019)
"Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment."	2.66	Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989)
"Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions."	2.48	Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012)
"Fatigue is recognized as one of the most disabling and common symptoms of MS."	2.44	Treating fatigue. ( Hum, S; Lapierre, Y, 2007)
"Fatigue is the most common symptom of MS and is associated with a reduced quality of life."	2.42	Management of fatigue in patients with multiple sclerosis. ( Zifko, UA, 2004)
"Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1."	2.41	Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001)
"Fatigue is a common symptom in patients with multiple sclerosis."	2.40	['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999)
"Multiple sclerosis is a demyelinating disorder of the central nervous system characterized by exacerbations and remissions of symptoms."	2.38	Update on multiple sclerosis therapy. ( Mitchell, G, 1993)
"Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection."	1.56	Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020)
"The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue."	1.34	Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). ( Antigüedad, AR; Benito-León, J; de Andrés, C; Frades, B; Huete-Antón, B; Martínez-Ginés, ML; Martínez-Martín, P; Meca-Lallana, JE; Rodríguez-García, E; Ruiz-Martínez, J, 2007)
"Fatigue is a common complaint in patients affected by multiple sclerosis."	1.31	[Therapeutic indications for managing symptoms: fatigue]. ( Waubant, E, 2001)
"We present a case of amantadine-induced coma in a patient with multiple sclerosis and end-stage renal disease."	1.29	Amantadine-induced coma. ( Ito, V; Macchio, GJ; Sahgal, V, 1993)

Research

Studies (66)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Acceptability of Treatment as Assessed by a Single Question Questionnaire

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (13.64)	18.7374
1990's	12 (18.18)	18.2507
2000's	20 (30.30)	29.6817
2010's	13 (19.70)	24.3611
2020's	12 (18.18)	2.80

Authors	Studies
Nourbakhsh, B	3
Bradley, L	1
Khodaie, F	1
Naser Moghadasi, A	1
Kazemi, AH	1
Zhao, B	1
Barbara, JM	1
Pace, A	1
Rocca, MA	2
Valsasina, P	2
Lamanna, MT	1
Colombo, B	2
Martinelli, V	2
Filippi, M	2
Rejdak, K	2
Grieb, P	2
Perez, DQ	1
Espiritu, AI	1
Jamora, RDG	1
Revirajan, N	2
Morris, B	1
Cordano, C	1
Creasman, J	1
Manguinao, M	1
Krysko, K	1
Rutatangwa, A	1
Auvray, C	1
Aljarallah, S	1
Jin, C	1
Mowry, E	1
McCulloch, C	1
Waubant, E	3
Bourdette, D	1
Świątkiewicz, M	1
Prus, K	1
Cohen, JA	2
Cameron, MH	1
Goldman, MD	1
Goodman, AD	1
Miller, AE	1
Rollins, A	1
Llorens, L	2
Patni, R	2
Elfont, R	1
Johnson, R	1
Yang, TT	1
Wang, L	1
Deng, XY	1
Yu, G	1
Hunter, SF	1
Brown, TR	1
Gudesblatt, M	1
Thrower, BW	1
Souza-Prien, CJ	1
Ruby, AE	1
Chernoff, DN	1
Sulkowski, G	1
Dąbrowska-Bouta, B	1
Strużyńska, L	1
Ledinek, AH	1
Sajko, MC	1
Rot, U	1
Mücke, M	1
Cuhls, H	1
Peuckmann-Post, V	1
Minton, O	1
Stone, P	1
Radbruch, L	2
Santarnecchi, E	1
Rossi, S	1
Bartalini, S	1
Cincotta, M	1
Giovannelli, F	1
Tatti, E	1
Ulivelli, M	1
Naumann, GO	1
Schlötzer-Schrehardt, U	1
Peuckmann, V	1
Elsner, F	1
Krumm, N	1
Trottenberg, P	1
Hood, CT	1
Langston, RH	2
Schoenfield, LR	1
Dupps, WJ	1
Tejani, AM	1
Wasdell, M	1
Spiwak, R	1
Rowell, G	1
Nathwani, S	1
Induruwa, I	1
Constantinescu, CS	1
Gran, B	1
Shaygannejad, V	1
Janghorbani, M	1
Ashtari, F	1
Zakeri, H	1
Foroughipour, M	1
Bahrami Taghanaki, HR	1
Saeidi, M	1
Khazaei, M	1
Sasannezhad, P	1
Shoeibi, A	1
Taus, C	2
Giuliani, G	2
Pucci, E	2
D'Amico, R	2
Solari, A	2
Bakshi, R	1
Tomassini, V	1
Pozzilli, C	1
Onesti, E	1
Pasqualetti, P	1
Marinelli, F	1
Pisani, A	1
Fieschi, C	1
Zifko, UA	1
Schwid, SR	1
Murray, TJ	2
Boggild, M	1
Ford, H	2
Hayes, BB	1
Cook-Norris, RH	1
Miller, JL	1
Rodriguez, A	1
Zic, JA	1
Debouverie, M	1
Pittion, S	1
Boërio, D	1
Lefaucheur, JP	1
Hogrel, JY	1
Créange, A	1
Nicholas, R	1
Axelrod, S	1
Bielory, L	1
Branãs, P	2
Benito-León, J	1
Martínez-Martín, P	1
Frades, B	1
Martínez-Ginés, ML	1
de Andrés, C	1
Meca-Lallana, JE	1
Antigüedad, AR	1
Huete-Antón, B	1
Rodríguez-García, E	1
Ruiz-Martínez, J	1
Lapierre, Y	1
Hum, S	1
Jeng, BH	1
Galor, A	1
Lee, MS	1
Meisler, DM	1
Hollyfield, JG	1
Schoenfield, L	1
McMahon, JT	1
Krupp, LB	3
Coyle, PK	2
Doscher, C	2
Miller, A	1
Cross, AH	1
Jandorf, L	1
Halper, J	1
Johnson, B	1
Morgante, L	1
Grimson, R	1
Mitchell, G	1
Macchio, GJ	1
Ito, V	1
Sahgal, V	1
Geisler, MW	1
Sliwinski, M	1
Masur, DM	1
Poser, CM	1
Dulli, D	1
Schutta, H	1
Huete, B	1
Varona, L	1
Zimmermann, C	1
Hohlfeld, R	1
Sailer, M	1
Heinze, HJ	1
Schoenfeld, MA	1
Hauser, U	1
Smid, HG	1
Jordan, R	1
Fry-Smith, A	1
Burls, A	1
Hyde, C	1
Christodoulou, C	1
Chiba, S	1
Ito, M	1
Matsumoto, H	1
Levy, M	1
Pastuszak, A	1
Koren, G	1
Wiggs, JW	1
de Roin, S	1
Winters, S	1
Maciejek, Z	1
Cohen, RA	1
Fisher, M	1
Rosenberg, GA	1
Appenzeller, O	1
Plaut, GS	1
Schapira, M	1
Fog, T	1
Potvin, AR	1
Albers, JW	1
Repa, BS	1
Henderson, WG	1
Walker, JE	1
Stribley, RF	1
Tourtellotte, WW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065]	Phase 3	141 participants (Actual)	Interventional	2017-10-04	Completed
A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093]		40 participants (Anticipated)	Observational	2022-04-30	Not yet recruiting
Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924]		42 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020]		100 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820]		105 participants (Actual)	Interventional	2017-05-31	Completed
A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525]	Phase 3	59 participants (Actual)	Interventional	2010-06-30	Completed
Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900]		0 participants (Actual)	Interventional	2012-02-29	Withdrawn (stopped due to Was unable to recruit subjects)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period

Epworth Sleepiness Scale (ESS) Score

Intervention	Participants (Count of Participants)
Placebo	39
Amantadine	41
Modafinil	55
Methylphenidate	55

ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period

Modified Fatigue Impact Scale (MFIS) Score

Intervention	score on a scale (Least Squares Mean)
Placebo	9.4
Amantadine	9.3
Modafinil	8.3
Methylphenidate	8.8

MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period

Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score

Intervention	score on a scale (Least Squares Mean)
Placebo	40.6
Amantadine	41.3
Modafinil	39.0
Methylphenidate	38.6

Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period

Article	Year
Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. Neurodegenerative disease management, 2020, Volume: 10, Issue:6 Topics: Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis	2020
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. Journal of the neurological sciences, 2017, Sep-15, Volume: 380 Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatig	2017
Pharmacological treatments for fatigue associated with palliative care. The Cochrane database of systematic reviews, 2015, May-30, Issue:5 Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea	2015
Pharmacological treatments for fatigue associated with palliative care. The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11 Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney	2010
Carnitine for fatigue in multiple sclerosis. The Cochrane database of systematic reviews, 2012, May-16, Issue:5 Topics: Acetylcarnitine; Adult; Amantadine; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trial	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Fatigue in multiple sclerosis - a brief review. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The	2012
Amantadine for fatigue in multiple sclerosis. The Cochrane database of systematic reviews, 2003, Issue:2 Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros	2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3 Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple	2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3 Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple	2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3 Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple	2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3 Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple	2003
Management of fatigue in patients with multiple sclerosis. Drugs, 2004, Volume: 64, Issue:12 Topics: Amantadine; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical	2004
Multiple sclerosis. Clinical evidence, 2004, Issue:12 Topics: Amantadine; Exercise Therapy; Glatiramer Acetate; Humans; Interferon-beta; Mitoxantrone; Multiple Sc	2004
[Pathophysiology and treatment of fatigue in multiple sclerosis]. Revue neurologique, 2006, Volume: 162, Issue:3 Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N	2006
Multiple sclerosis. Clinical evidence, 2005, Issue:14 Topics: Adrenal Cortex Hormones; Amantadine; Azathioprine; Glatiramer Acetate; Humans; Immunoglobulins, Intr	2005
Amantadine for fatigue in multiple sclerosis. The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1 Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros	2007
Treating fatigue. International MS journal, 2007, Volume: 14, Issue:2 Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents	2007
Update on multiple sclerosis therapy. The Medical clinics of North America, 1993, Volume: 77, Issue:1 Topics: Amantadine; Baclofen; Fatigue; Humans; Immunosuppression Therapy; Interferons; Multiple Sclerosis; M	1993
['Fatigue' in multiple sclerosis]. Der Nervenarzt, 1999, Volume: 70, Issue:6 Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis;	1999
Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health technology assessment (Winchester, England), 2000, Volume: 4, Issue:27 Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Base	2000
Fatigue in multiple sclerosis. Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3 Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste	2001
Fetal outcome following intrauterine amantadine exposure. Reproductive toxicology (Elmsford, N.Y.), 1991, Volume: 5, Issue:1 Topics: Adult; Amantadine; Animals; Embryonic and Fetal Development; Female; Follow-Up Studies; Humans; Mate	1991
Amantadine hydrochloride: current and new uses. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 1990, Volume: 22, Issue:5 Topics: Amantadine; Humans; Influenza, Human; Multiple Sclerosis; Parkinson Disease	1990
Quantitative evaluation of neuropharmacological trials. Clinical pharmacology and therapeutics, 1974, Volume: 15, Issue:3 Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin	1974

Article	Year
Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial. Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2023, Volume: 41, Issue:4 Topics: Acupuncture Therapy; Amantadine; Fatigue; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-	2023
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine. Journal of neurology, 2023, Volume: 270, Issue:10 Topics: Amantadine; Brain; Brain Mapping; Dopamine; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sc	2023
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. The Lancet. Neurology, 2021, Volume: 20, Issue:1 Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug	2021
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. The Lancet. Neurology, 2021, Volume: 20, Issue:1 Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug	2021
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. The Lancet. Neurology, 2021, Volume: 20, Issue:1 Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug	2021
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. The Lancet. Neurology, 2021, Volume: 20, Issue:1 Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug	2021
Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. European journal of neurology, 2021, Volume: 28, Issue:7 Topics: 4-Aminopyridine; Amantadine; Brain; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sclerosis	2021
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple sclerosis (Houndmills, Basingstoke, England), 2022, Volume: 28, Issue:5 Topics: 4-Aminopyridine; Adult; Amantadine; Delayed-Action Preparations; Double-Blind Method; Humans; Multip	2022
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemporary clinical trials, 2018, Volume: 64 Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum	2018
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple sclerosis (Houndmills, Basingstoke, England), 2019, Volume: 25, Issue:4 Topics: Adult; Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Dyskines	2019
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. Clinical neurology and neurosurgery, 2013, Volume: 115 Suppl 1 Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans	2013
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological research, 2012, Volume: 34, Issue:9 Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross	2012
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the neurological sciences, 2004, Mar-15, Volume: 218, Issue:1-2 Topics: Acetylcarnitine; Adult; Amantadine; Analgesics, Non-Narcotic; Analysis of Variance; Confidence Inter	2004
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology, 1995, Volume: 45, Issue:11 Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind	1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology, 1995, Volume: 45, Issue:11 Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind	1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology, 1995, Volume: 45, Issue:11 Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind	1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology, 1995, Volume: 45, Issue:11 Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind	1995
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of neurology, 1996, Volume: 53, Issue:2 Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; C	1996
Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry, 2000, Volume: 33, Issue:1 Topics: Adult; Amantadine; Attention; Brain; Cognition; Dopamine Agents; Double-Blind Method; Evoked Potenti	2000
Changes in visual evoked potentials in patients with multiple sclerosis treated with isoprinosine and amantadine. Archivum immunologiae et therapiae experimentalis, 1989, Volume: 37, Issue:5-6 Topics: Adolescent; Adult; Amantadine; Evoked Potentials, Visual; Female; Humans; Inosine Pranobex; Male; Mu	1989
Amantadine treatment of fatigue associated with multiple sclerosis. Archives of neurology, 1989, Volume: 46, Issue:6 Topics: Adult; Amantadine; Circadian Rhythm; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis;	1989
A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1987, Volume: 14, Issue:3 Topics: Activities of Daily Living; Adult; Amantadine; Clinical Trials as Topic; Depression; Double-Blind Me	1987
Amantadine, fatigue, and multiple sclerosis. Archives of neurology, 1988, Volume: 45, Issue:10 Topics: Amantadine; beta-Endorphin; beta-Lipotropin; Disability Evaluation; Fatigue; Humans; Lactates; Lacti	1988
Effectiveness of amantadine in reducing relapses in multiple sclerosis. Journal of the Royal Society of Medicine, 1987, Volume: 80, Issue:2 Topics: Adult; Amantadine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged;	1987
Amantadine therapy for fatigue in multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1985, Volume: 12, Issue:3 Topics: Amantadine; Clinical Trials as Topic; Fatigue; Humans; Multiple Sclerosis	1985
Quantitative evaluation of neuropharmacological trials. Clinical pharmacology and therapeutics, 1974, Volume: 15, Issue:3 Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin	1974

Article	Year
Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue. Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:14 Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Risk Assessment	2021
Delayed amantadine toxicity causing apparent progression of multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:14 Topics: Amantadine; Disease Progression; Fatigue; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Ch	2021
Amantadine toxicity causing visual hallucinations. Practical neurology, 2023, Volume: 23, Issue:5 Topics: Amantadine; Antiparkinson Agents; Female; Hallucinations; Humans; Levodopa; Multiple Sclerosis	2023
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple sclerosis and related disorders, 2020, Volume: 42 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co	2020
Are drugs for multiple sclerosis fatigue just placebos? The Lancet. Neurology, 2021, Volume: 20, Issue:1 Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph	2021
Amantadine for COVID-19. Journal of clinical pharmacology, 2021, Volume: 61, Issue:3 Topics: Amantadine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fatigue; Humans; Multiple Sclerosis	2021
Modulation of neurological deficits and expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors. BioMed research international, 2013, Volume: 2013 Topics: Amantadine; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory	2013
Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine. Neural plasticity, 2015, Volume: 2015 Topics: Adult; Amantadine; Evoked Potentials, Motor; Fatigue; Female; Fingers; Humans; Male; Middle Aged; Mo	2015
Amantadine-associated corneal edema. Ophthalmology, 2009, Volume: 116, Issue:6 Topics: Amantadine; Analgesics, Non-Narcotic; Bipolar Disorder; Corneal Edema; Dopamine Agents; Humans; Kera	2009
Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye, 2010, Jul-29, Volume: 41 Online Topics: Amantadine; Automation; Corneal Edema; Descemet Stripping Endothelial Keratoplasty; Diagnosis, Diffe	2010
Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2013, Volume: 31, Issue:1 Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Amantadine; Child; Drug Resistance; Fatigue; Female; H	2013
Treating fatigue in patients with MS: one step forward, one step back. Neurology, 2005, Apr-12, Volume: 64, Issue:7 Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants	2005
Amantadine-induced livedo reticularis: a report of two cases. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:3 Topics: Aged; Amantadine; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Leg; Middle Aged; M	2006
[Fatigue and episodic exhaustion as a feature of multiple sclerosis]. Revue neurologique, 2006, Volume: 162, Issue:3 Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed	2006
Beta2-agonists and paresthesias in multiple sclerosis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 98, Issue:1 Topics: Adrenergic beta-Agonists; Albuterol; Amantadine; Analgesics, Non-Narcotic; Androstadienes; Aromatase	2007
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). Multiple sclerosis (Houndmills, Basingstoke, England), 2007, Volume: 13, Issue:5 Topics: Adolescent; Adult; Aged; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Dopami	2007
Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. Ophthalmology, 2008, Volume: 115, Issue:9 Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Bipolar Disorder; Corneal Edema; Dopamine Agents; Femal	2008
Amantadine-induced coma. Archives of physical medicine and rehabilitation, 1993, Volume: 74, Issue:10 Topics: Adult; Amantadine; Coma; Humans; Kidney Failure, Chronic; Male; Multiple Sclerosis	1993
Fatigue in MS. Neurology, 1996, Volume: 47, Issue:5 Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis	1996
Fatigue in MS. Neurology, 1996, Volume: 47, Issue:5 Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline	1996
[Insomnia during treatment with amantadine]. Revista de neurologia, 1997, Volume: 25, Issue:148 Topics: Adult; Amantadine; Dopamine Agents; Fatigue; Humans; Male; Multiple Sclerosis; Sleep Initiation and	1997
[Therapeutic indications for managing symptoms: fatigue]. Revue neurologique, 2001, Volume: 157, Issue:8-9 Pt 2 Topics: Amantadine; Aminopyridines; Double-Blind Method; Fatigue; Humans; Multiple Sclerosis; Randomized Con	2001
Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1992, Volume: 19, Issue:2 Topics: Adult; Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pain	1992
Amantidine, the old anti-Parkinson medication, being useful in the fatigue syndrome that often accompanies multiple sclerosis. South Dakota journal of medicine, 1991, Volume: 44, Issue:9 Topics: Amantadine; Fatigue; Fatigue Syndrome, Chronic; Humans; Male; Middle Aged; Multiple Sclerosis; Parki	1991
Treating multiple sclerosis with amantadine hydrochloride. The Journal of the Royal College of General Practitioners, 1974, Volume: 24, Issue:143 Topics: Amantadine; Diplopia; Humans; Male; Middle Aged; Multiple Sclerosis; Speech Disorders; Vertigo	1974
[Letter: Amantadine treatment in disseminated sclerosis]. Ugeskrift for laeger, 1974, Nov-18, Volume: 136, Issue:47 Topics: Amantadine; Humans; Multiple Sclerosis	1974

amantadine and MS (Multiple Sclerosis)